Advances in Cancer Genomics and Precision Oncology

Overview

Journal Genes Genomics

Date 2025 Jan 23

PMID 39849190

Authors

Yonjong Heo

Woo-Jin Kim

Yong-Joon Cho

Jae-Won Jung

Nam-Soo Kim

Ik-Young Choi

Affiliations

Soon will be listed here.

Abstract

Background: Next-generation sequencing has revolutionized genome science over the last two decades. Indeed, the wealth of sequence information on our genome has deepened our understanding on cancer. Cancer is a genetic disease caused by genetic or epigenetic alternations that affect the expression of genes that control cell functions, particularly cell growth and division. Utilization of next-generation sequencing in cancer gene panels has enabled the identification of actionable gene alterations in cancer patients to guide personalized precision medicine.

Objective: The aim is to provide information that can identify actionable gene alterations, enabling personalized precision medicine for cancer patients.

Results & Discussion: Equipped with next-generation sequencing techniques, international collaboration programs on cancer genomics have identified numerous mutations, gene fusions, microsatellite variations, copy number variations, and epigenetics changes that promote the transformation of normal cells into tumors. Cancer classification has traditionally been based on cell type or tissue-of-origin and the morphological characteristics of the cancer. However, interactive genomic analyses have currently reclassified cancers based on systemic molecular-based taxonomy. Although all cancer-causing genes and mechanisms have yet to be completely understood or identified, personalized or precision medicine is now currently possible for some forms of cancer. Unlike the "one-size-fits-all" approach of traditional medicine, precision medicine allows for customized or personalized treatment based on genomic information.

Conclusion: Despite the availability of numerous cancer gene panels, technological innovation in genomics and expansion of knowledge on the cancer genome will allow precision oncology to manage even more types of cancers.

References

Adamo P, Ladomery M . The oncogene ERG: a key factor in prostate cancer. Oncogene. 2015; 35(4):403-14. DOI: 10.1038/onc.2015.109. View

Agarwal P, Sandey M, DeInnocentes P, Bird R . Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer. J Cell Biochem. 2012; 114(6):1355-63. DOI: 10.1002/jcb.24476. View

Allis C, Jenuwein T . The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016; 17(8):487-500. DOI: 10.1038/nrg.2016.59. View

Altelaar A, Munoz J, Heck A . Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2012; 14(1):35-48. DOI: 10.1038/nrg3356. View

Aoude L, Wadt K, Pritchard A, Hayward N . Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 2014; 28(2):148-60. DOI: 10.1111/pcmr.12333. View

Ashley E . Towards precision medicine. Nat Rev Genet. 2016; 17(9):507-22. DOI: 10.1038/nrg.2016.86. View

Bannister A, Kouzarides T . Regulation of chromatin by histone modifications. Cell Res. 2011; 21(3):381-95. PMC: 3193420. DOI: 10.1038/cr.2011.22. View

Barista I, Romaguera J, Cabanillas F . Mantle-cell lymphoma. Lancet Oncol. 2002; 2(3):141-8. DOI: 10.1016/S1470-2045(00)00255-2. View

Bassi N, Hovland H, Rasheed K, Jarhelle E, Pedersen N, Mchaina E . Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays. BMC Cancer. 2023; 23(1):368. PMC: 10122298. DOI: 10.1186/s12885-023-10790-w. View

10.

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

11.

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

12.

Bert S, Robinson M, Strbenac D, Statham A, Song J, Hulf T . Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 2012; 23(1):9-22. DOI: 10.1016/j.ccr.2012.11.006. View

13.

Boland C, Goel A . Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6):2073-2087.e3. PMC: 3037515. DOI: 10.1053/j.gastro.2009.12.064. View

14.

Bouwman P, Jonkers J . The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012; 12(9):587-98. DOI: 10.1038/nrc3342. View

15.

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

16.

Byeon I, Li J, Ericson K, Selby T, Tevelev A, Kim H . Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell. 1998; 1(3):421-31. DOI: 10.1016/s1097-2765(00)80042-8. View

17.

Catana A, Apostu A, Antemie R . Multi gene panel testing for hereditary breast cancer - is it ready to be used?. Med Pharm Rep. 2019; 92(3):220-225. PMC: 6709965. DOI: 10.15386/mpr-1083. View

18.

Chakravarty D, Solit D . Clinical cancer genomic profiling. Nat Rev Genet. 2021; 22(8):483-501. DOI: 10.1038/s41576-021-00338-8. View

19.

Chen M, Zhao H . Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019; 13(1):34. PMC: 6669976. DOI: 10.1186/s40246-019-0220-8. View

20.

Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X . Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022; 13(11):974. PMC: 9674619. DOI: 10.1038/s41419-022-05408-1. View